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ABSTRACT
Study Protocol: Investigating the Effects of Uncarboxylated Osteocalcin and Anodal
Trans-Spinal Direct Current Stimulation on Recovery Post-Spinal Cord Injury in Mouse
Model

By: WingTo Ip, Brandon Nam and Parth Shah
Faculty Advisor: Dr. Jean-Phillippe Berteau BPT, MSc, PhD

Individuals with spinal cord injury often present with severe neuromuscular
spasticity due to over-secretion of the neurotransmitter known as gamma-aminobutyric
acid (GABA). Spasticity is made worse by the other sequelae of SCI, including muscle
atrophy and loss of bone mineral density. This manuscript presents a study protocol that
attempts to target such widespread physiological changes affecting multiple body
systems. Our protocol establishes a potential treatment approach for SCI by combining
recent advances in literature with a novel approach never seen before. We hypothesize
that the use of the already-promising anodal trans-spinal direct current stimulation (ATSDCS) along with exogenous administration of a naturally occurring biomolecule called
uncarboxylated osteocalcin, will reduce spasticity, increase muscle mass and restore or
maintain bone mineral density. We expect these changes to be more pronounced when
compared to those expected with the individual treatment approaches. Our manuscript
delineates a comprehensive experimental design, as supported by similar study setups in
related research, which will help achieve these aims.
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INTRODUCTION
Individuals who survive spinal cord injury (SCI) often present with debilitating

symptoms that negatively impact the neuromuscular and musculoskeletal systems, such
as spasticity and impaired bone biomechanical properties (Battafarano et al., 2020;
Mekhael et al., 2019). Spasticity is characterized by increased muscle activity during
passive stretch (Katz and Rymer, 1989) (Lance, 1980) due to hyperexcitability of alpha
motor neurons (Mayer, 1997) and interneurons (Elbasiouny & Mushahwar, 2007;
Elbasiouny et al., 2010). It can range from mild to severe and can cause striking
impairments in functional movement (Adams and Hicks, 2005). While one explanation is
the over-secretion of gamma-aminobutyric acid (GABA) for the onset of spasticity postSCI (Huang et al., 2016; Boulenguez et al., 2010), recent evidence suggests that an
increase in muscle tone and a decrease in muscle mass intensifies it (Mekhael et al.,
2019). Besides changes in muscle mass and tone, there is also a significant reduction in
bone mineral density (BMD) due to decreased weight-bearing, which often results in a
higher risk of bone fractures (Battafarano et al., 2020; Mekhael et al., 2019). Thus, a
comprehensive treatment of SCI is particularly challenging because of the presence of
such widespread physiological changes affecting multiple body systems.
Regarding spasticity, one intervention that has shown some promise is anodal
trans-spinal direct current stimulation (A-TSDCS). This intervention reduces spasticity by
inhibiting GABA secretion; however, the effect is transient and does not address the
numerous musculoskeletal deficits associated with SCI (Ahmed et al., 2011; Ahmed,
2011; Ahmed, 2013; Ahmed & Wieraszko, 2012; Mekhael et al., 2019). An alternative
solution that targets GABA over-secretion, is osteocalcin (OC). OC is a bone protein made
by osteoblasts and its uncarboxylated form (uOC) that is released during bone remodeling,
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acts as an endocrine hormone targeting the brain, pancreas, bone and muscle. In addition
to uOC decreasing GABA production in the brainstem (Oury et al., 2013), the protein also
maintains muscle mass in a pre-clinical model of aging in mice (Mera et al., 2016b).
Furthermore, other research has demonstrated uOC’s role in muscle metabolism by
improving exercise capacity (Tsuka et al., 2015; Mera et al., 2016a; Lin et al., 2017),
muscle mass (Mera et al., 2016a; Mera et al., 2016b), insulin sensitivity and secretion (Lee
et al., 2007; Fulzele et al., 2010; Ferron et al., 2012; Sabek et al., 2015), glucose and fatty
acid metabolism (Fulzele et al., 2010; Ferron et al., 2012; Huang et al., 2017) — we
summarized the relevant effects of uOC in Figure 1. Thus, evidence establishes that uOC
decreases GABA production and increases muscle mass independently (Oury et al., 2013;
Mera et al., 2016b). Since spasticity post-SCI is characterized by an increase in GABA
and exacerbated with muscle atrophy (Huang et al., 2016; Boulenguez et al., 2010;
Mekhael et al., 2019), the aforementioned uOC-induced changes can potentially
contribute towards a reduction in spasticity. However, current research has not yet
explored these particular effects in a SCI model.
The main objectives of this proposal are to establish an experimental design and
study protocol that will examine the effects of supplemental uOC administration with and
without A-TSDCS on spasticity, muscle mass and bone biomechanical properties
following SCI (Figure 2). We hypothesize that uOC alone will reduce spasticity post-SCI
directly by decreasing GABA production and indirectly by increasing muscle mass. We
also expect that the combined interventions of uOC and A-TSDCS will reduce spasticity
earlier and further than either of the interventions alone, likely due to their synergistic effect
on decreasing GABA secretion. To test our hypotheses, we will use a pre-clinical model
of SCI in mice that will correlate well, in terms of clinical presentation, with chronic SCI in
humans. In addition, we will administer uOC via subcutaneous osmotic pumps and follow
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previously designed and verified protocols (Ferron et al., 2008 & Mera et al., 2016b) to
establish this biomolecule’s effect on spasticity and muscle mass. Furthermore, we will
also administer A-TSDCS alone and with uOC to investigate their potential of a synergistic
effect on spasticity.

2

MATERIALS AND METHODS

2.1 Sample Preparation
Fifty CD-1 mice are bred for 8 weeks in the Animal Facility of CSI, Building 6S
Room 03, until reaching sexual maturity. For our study, we will only use female mice to
avoid the confounding effect of testosterone on muscle mass production (Mera et al.,
2016b). An incomplete SCI will be induced in all subjects, after which the mice will received
assigned interventions 1 week thereafter (Figure 3). This 1-week delay ensures that the
injury enters the subacute phase of recovery in the subjects (Marinelli et al., 2019).
Evidence shows that the subacute phase in rodents is marked by significant spasticity,
muscle atrophy and loss of BMD, the presence of which most closely identifies with the
beginning of chronic SCI in humans (Marinelli et al., 2019; Rowland et al., 2008; Lin et al.,
2015). The animals are housed individually in standard polycarbonate cages throughout
their lifespan until euthanasia. Specific animal monitoring and housing parameters will be
followed as previously established in literature (Ahmed, 2017).
2.2 Spinal Cord Injury
Mice are administered a ketamine/xylazine cocktail (90/10 mg/kg) for
anesthetization after which a laminectomy procedure will be performed at the T10
vertebrae to expose the T13 spinal segment. Second, a SCI is induced via the Infinite
Horizon (IH) spinal cord impactor (IH-0400, Precision Systems and Instrumentation, VA,
3

USA) at a force level of 60 kdyn with a standard mouse tip (1.3mm in diameter). The
impact force level of 60 kdyn is selected based on data collected from exploratory
experiments that were conducted with this impactor (Mekhael et al., 2019). It was found
that mice impacted with this force level exhibit spastic behavior 2-3 weeks post-SCI injury
(Mekhael et al., 2019). Third, mice are sutured, given 1.64 mg/ml dose of acetaminophen
orally to reduce pain and heated on a warming pad (30° Celsius) with daily examinations
conducted to assess wound healing. Subcutaneous saline injections will assist with
hydration while DietGel (ClearH2O, Westbrook, ME, USA) and crushed Purina Mouse
Chow (LabDiet, St Louis, MO, USA) will assist with feeding.
2.3 Experimental Setup
The mice are randomly assigned into five groups of ten mice each, by a researcher
not intimately aware of our study protocol. The five groups are as follows: mice with SCI;
mice with SCI receiving Dose I of uOC at 30ng/hour; mice with SCI receiving Dose II of
uOC at 90ng/hour; mice with SCI receiving A-TSDCS; and mice with SCI receiving ATSDCS and Dose II of uOC at 90ng/hour. This aforementioned study design is described
in Figure 3. A-TSDCS parameters are based on procedure previously published (Mekhael
et al., 2019). All investigators involved in the experiment, including in setup, data collection
and analysis, will be aware of group allocation.
2.4 Osteocalcin Administration
Three groups of mice receive supplemental uOC for 28 days via subcutaneous
osmotic pumps (Alzet Model 1004); two groups receive 90 ng/hour (Dose II) and one
receive 30 ng/hour (Dose I), as seen in Figure 3. The subcutaneous pumps will be
implanted into mice receiving uOC (n = 30). These particular dosage protocols were used
in two different studies. One examined the impact of supplemental uOC (Dose II) on
4

muscle mass maintenance in aging mice (Mera et al., 2016b). Another established optimal
uOC dosage (Dose I) to maximize insulin sensitivity and glucose catabolism (Ferron et al.,
2008). Lastly, the pump implantation procedure was provided by Alzet® Osmotic Pumps
(DURECT Corporation, Cupertino, CA, USA).
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OUTCOME MEASUREMENT AND DATA ANALYSIS

3.1 Spasticity Testing
Spasticity is examined twice in both groups, once at the halfway point (14 days)
and second, at the end of the study period (28 days). The mice are restrained using a
mouse restrainer that was constructed in our lab. The mice are given three days (30
min/day) in the mouse restrainer to acclimatize before spasticity is measured. Spasticity
testing is done with mice asleep via isoflurane administration, then held dorsally with their
hind limbs elevated and supported by ankle and knee stabilizers. A stretch apparatus is
used to stretch the triceps surae muscles at three different speeds (18° s−1, 180° s−1 &
1800° s−1). Each stretch is separated by two 10-sec intervals for recovery. Software
programs (DMX-UMD GUI, ARCUS Technology Inc.; LabChart-7 Bundled with PowerLab
Data Acquisition System Software, ADInstruments) are used to control the stepper-motor
in order to perform stretch and electromyographic (EMG) readings.
3.2 Euthanasia and Bone Harvesting
Following completion of experimental protocol, the mice are euthanized and their
bones (femur with both condyles) harvested for biomechanical assessment. Mice are
sacrificed using carbon dioxide asphyxiation (2.5 L/min) followed by cervical dislocation.
Femur bones are prepared with low speed diamond saw (thickness 0.3 mm) (Isomet,
Buelher, Lake Bluff, IL, USA) under constant irrigation with phosphate Buffered Saline
5

(PBS) and Protease Inhibitor (PI) at a speed of 60 rpm. Bone samples will be stored at 20°C in our laboratory.
3.3 Histomorphometry
Following euthanasia and PBS perfusion, the mice are first weighed and then, the
posterior hind limbs dissected to remove the triceps surae muscle. The ratio of triceps
surae muscle weight to preoperative body weight is calculated. The muscle samples are
frozen in liquid nitrogen and stored at -80°C while awaiting histological examination. The
samples are fixed in 10% phosphate-buffered formaldehyde solution to allow dehydration
and decalcification, before being embedded in paraffin and stained using hematoxylin and
eosin. Muscle fibers are evaluated using Nikon ECLIPSE TS100 light microscope (Tokyo,
Japan) and Nikon D7200 image acquisition system, with their diameters measured using
Image J software (National Institutes of Health, Bethesda, MD, USA).
3.4 High Resolution Micro-Computed Tomography
Tissue mineral density of bone samples is evaluated using high-resolution microcomputed tomography (HR-µCT, SCANCO Medical AG). To maximize resolution, the
following parameters may be used – Voxel Size: 1.2 µm, Field of View: 4.080 mm, Image
Matrix: 2500 x 2500 x 850, Slices: 850, Scanned Region: 1.10 mm, X-Ray Voltage: 90
kVp, Intensity: 44 µA, Projections/180°: 1500, Integration Time: 1500 ms, Frame
Averaging: 4, Filter AL: 0.5 mm and Scanning Time: 6.8 hours. The scanning will include
both lateral and medial condyles. A 3D matrix will be obtained by computing 2D slices of
HR-µCT acquisition via a code of segmentation adapted from a previously published paper
(Mehadji et al., 2019) in Matlab (MATLAB, MathWorks Inc., Natick, MA, USA). 3D
visualization of each mineralized layer will be performed using Image J (Schneider et al.,
2012).
6

3.5 Three Point Bending
Three-point bending strength will be measured with a constant span length of
10 mm. This length has been successfully used in past experiments and is preferred for
mouse long bone because it increases the aspect ratio and leads to less error when tissue
mechanical properties are computed (Berteau et. al, 2014). Bones are tested in the anteroposterior axis with the posterior surface facing upward, centered on the support and the
pressing force applied vertically to the midshaft of the bone. Each bone is tested with a
loading speed of 2 mm·min−1 until failure with a 100 N load cell on an ADMET
Compression Machine and the load-displacement curve recorded at a 100 Hz rate by the
MTESTQuarttro software. The following properties will be examined: Young’s Modulus,
Yield and Max Stress, Yield and Max Strain, Elastic Work, Plastic Work and Total Work.
3.6 Raman Spectroscopy
Raman spectroscopy is conducted using an Alpha300 R Raman Microscope
(WITec, Ulm, Germany). Compositional parameters will be investigated using a
customized MATLAB program (MATLAB, MathWorks Inc., Natick, MA, USA) from a
previously published paper (Fayolle et al., 2019). The femurs are imaged at the proximal
end, distal end, and one point at the center. Several bone biomechanical properties are
examined, including the Mineral-to-Matrix Ratio, Carbonate-to-Phosphate Ratio,
Carbonate-to Amide-I Ratio, Crystallinity and Collagen Maturity.
3.7 Statistical Analysis
All statistical analyses will be performed using SPSS software (IBM SPSS
Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp., 2015) and data will be
reported as mean ± [SD/mean]. The Anderson-Darling test will be used to identify
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normality of the data collected. A student’s t-test is performed for data falling within normal
distribution; otherwise, a Mann-Whitney U test will be used for non-parametric data, where
applicable. Power analysis will be conducted to determine the appropriate sample size
needed to reduce the risk of type II error. Significance level used will be ɑ = 0.05.

4

POTENTIAL PITFALLS
There are several potential pitfalls present in our study. First limitation can be from

our method of data collection, specifically regarding the use of our laboratory-created
spasticity-measuring apparatus. Since the apparatus is custom designed in our lab, there
is no test of reliability for it in existing literature. Certain studies have investigated the
reliability of the isokinetic dynamometer, an instrument that works similar to our own
apparatus – by stretching the limb at different angular velocities. These studies found that
the isokinetic dynamometer is 75-90% reliable in measuring spasticity in humans (Starsky
et al., 2005; Denho et al., 2020). However, this measure of reliability is questionable,
especially since our study only uses mice. In addition, there are certain pathophysiological
differences in onset and progression of spasticity post-SCI between mice and humans
that may make cross-species comparisons difficult (Marinelli et al., 2019; Rowland et al.,
2008; Lin et al., 2015).
Second potential limitation is in our SCI model. Other SCI models more accurately
mimic human SCI in mice than our laminectomy-based contusion method. One such
method is the dislocation model: it dislocates a vertebral segment and allows for a more
accurate representation of human traumatic SCI without the need for performing a
laminectomy (Cheriyan et al., 2014; Marinelli et al., 2019). Conducting a laminectomy
before the contusion impact limits the stress dealt to the spinal cord in our study. This can
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possibly decrease the post-SCI BMD loss and thus, alter the effect size of the proposed
interventions.
Third potential limitation is that our study focuses primarily on female mice who
have just reached sexual maturity. Since males have a higher incidence of SCI than
females, the results of our study are not easily related to the observed general trend
(McCaughey et al., 2015). In addition, age is another demographic factor that our study
does not account. The average age of human SCI between 2010 and 2014 was 42.2
years, a number significantly past sexual maturity – again resulting in data that will be hard
to extrapolate to the general SCI population (Chen et al., 2014).
Fourth potential limitation exists in our use of uOC. Our protocol examines the
effect of two particular dosages of uOC (Dose I of 30 ng/hour and Dose II of 90 ng/hour)
on the effects of SCI; however, this precludes the ability to test uOC’s effect along a
continuum of subcutaneous administration. This can be ameliorated by conducting a
sensitivity study of uOC following completion of our proposed protocol. Another pitfall
emerges from conducting our experiment on 8-week old sexually mature, newly adult CD1 mice. We know that uOC has a pronounced effect on increasing muscle mass with aging,
as studied by Mera and colleagues (Mera et al., 2016b). As a result, a limitation of our
study is in not being able to examine the longitudinal effect of uOC on muscle mass
production, especially within the context of an aging mouse model.
Lastly, another potential limitation exists in attributing BMD and muscle mass
recovery solely due to the proposed interventions. Mice that perform voluntary muscle
contractions may gain BMD or muscle mass independently or in addition to the increases
caused by uOC or A-TSDCS. By not being able to place appropriate restrictions on the
amount of muscle contraction performed, any resulting change in BMD or muscle mass
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can be attributed to either the proposed intervention or the confounding variable. Another
possibility is that increased bone loading can cause a successive release of uOC from
bone (Battafarano et al., 2020), which will elevate uOC levels in blood and potentially
amplify the effects of uOC on muscle mass production and/or spasticity.

FIGURES
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Figure 3 Details of the experimental setup are noted above, with the
legend providing the key for the symbols used in the figure.
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SUPPLEMENTARY MATERIALS
Aims and Expected Outcomes
Aim 1: Establish the role of the different uOC dosages in regulating muscle
spasticity, bone resorption and muscle atrophy after SCI in mouse model
1. We will administer uOC in different concentrations (Dose I = 30 ng/hour, Dose II =
90 ng/hour) into two different groups of SCI mouse subjects. Comparisons will be
made between the experimental groups and the control group to establish a
relationship of the treatment effect.
2. Expected Outcomes:
a. We expect to see a reduction in level of spasticity as well as increase in
muscle mass with the higher uOC dosage (Dose II) only
b. We also expect to see improved bone parameters, primarily Young’s
Modulus, with both uOC dosages.
Aim 2: Establish the combined effect of uOC with A-TSDCS on spasticity after SCI
in mouse model
1. We will administer uOC at 90ng/hour (Dose II) along with A-TSDCS in one group
and administer A-TSDCS to another group to explore their individual and
potentiated effects in reducing spasticity after SCI in mice.
2. Expected Outcomes:
a. We expect to see a greater reduction of spasticity with the combined
intervention as opposed to the standalone interventions of A-TSDCS or
uOC.
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